RudaCure is also actively pursuing marché mondial entry. L'entreprise established an overseas subsidiary in 2021 and participates in major pharmaceutique/bio exhibition partenariat events tels que JPM, Bio-Europe, and Bio-USA to attract overseas investissement and transferts de technologie. L'entreprise is also engaged with overseas accelerators notamment KIC (Korea Innovation Center), the U.S. Mass Challenge program, and the Shinhan Square Bridge Global Program, ainsi que U.S. bio events notamment UKC2022 and the RESI Conference. Most récemment, l'entreprise won awards at IR competitions at UKC2022 (Washington D.C.) and RESI Conference (Boston).
Regarding future plans, le PDG Kim a déclaré : "We will advance RCI001 national essais cliniques de Phase 1 within cette année," adding, "Our goal is to proceed with U.S. FDA essais cliniques de Phase 2 by the first half of 2023."
Founded: July 2018
Main business: New développement de médicaments notamment sécheresse oculaire and chronic traitement de la douleurs
Achievements: Certified corporate R&D center (2019.1), Certified venture company (2019.5), Technology-innovant SME certification (2022.3), Ministère de Employment and Labor Strong Small Enterprise designation (2022.05). RCI001 sécheresse oculaire treatment: 1 demande de brevet + 2 patents registered; RCI002 chronic traitement de la douleur: 5 demandes de brevets + 1 patent registered; 2 développement conjoint patents registered; 2 trademark registrations; KRW 15 billion joint R&D accord with Hanlim Pharmaceutical; KRW 6 billion Series A investissement completed (2022.5); RudaCure U.S.A. incorporated (2021.08); Expanded to dual Songdo HQ and Seoul branch structure (2022.07); 2022 Korean-American Scientists Conference SBA Award; RESI Conference pitch competition award winner
📊 Related Materials & Evidence
[Patent certificate image slot]Patent Registration Certificate (RCI001)
[Event photo image slot]RESI Conference on-site
🔗 Related Links: